期刊
MOLECULES
卷 27, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/molecules27082394
关键词
silmitasertib; CX-4945; LC-MS; MS; liquid-liquid extraction; validation; plasma
Silmitasertib is a drug currently being investigated in clinical trials for the treatment of various cancers. It inhibits CK2 protein kinase, which has proliferation-promoting and anti-apoptotic effects on cancer cells. Researchers have developed an LC-MS/MS method for quantifying silmitasertib in human plasma.
Silmitasertib (CX-4945) is currently being investigated in clinical trials against various types of cancer. The U.S. Food and Drug Administration (FDA) has already granted orphan drug designation to the compound for the treatment of advanced cholangiocarcinoma, medulloblastoma, and biliary tract cancer. Silmitasertib inhibits the serine/threonine protein kinase CK2, which exerts a proliferation-promoting and anti-apoptotic effect on cancer cells. In view of current and future applications, the measurement of silmitasertib levels in plasma is expected to play an important role in the evaluation of therapeutic and toxic concentrations in cancer patients. In the present work, we therefore present an LC-MS/MS method for the quantification of silmitasertib in human plasma. Using a simple liquid-liquid extraction with ethyl acetate and a mixture of n-hexane and ethyl acetate, this method can be performed in any laboratory with mass spectrometry. The validation was carried out according to the FDA guideline.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据